补体依赖性细胞溶解作用：广谱交叉反应性人源单克隆抗体对甲型流感病毒感染细胞的作用。
Complement-dependent lysis of influenza a virus-infected cells by broadly cross-reactive human monoclonal antibodies.
机构信息
Center for Infectious Disease and Vaccine Research, Division of Infectious Diseases and Immunology, Department of Medicine, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655, USA.
出版信息
J Virol. 2011 Dec;85(24):13463-7. doi: 10.1128/JVI.05193-11. Epub 2011 Oct 12.
Abstract
We characterized human monoclonal antibodies (MAbs) cloned from influenza virus-infected patients and from influenza vaccine recipients by complement-dependent lysis (CDL) assay. Most MAbs active in CDL were neutralizing, but not all neutralizing MAbs can mediate CDL. Two of the three stalk-specific neutralizing MAbs tested were able to mediate CDL and were more cross-reactive to temporally distant H1N1 strains than the conventional hemagglutination-inhibiting and neutralizing MAbs. One of the stalk-specific MAbs was subtype cross-reactive to H1 and H2 hemagglutinins, suggesting a role for stalk-specific antibodies in protection against influenza illness, especially by a novel viral subtype which can cause pandemics.
摘要
我们通过补体依赖性裂解（CDL）试验对从流感病毒感染患者和流感疫苗接种者中克隆的人源单克隆抗体（MAb）进行了表征。在 CDL 中具有活性的大多数 MAb 是中和性的，但并非所有中和性 MAb 都能介导 CDL。在所测试的三种茎特异性中和 MAb 中，有两种能够介导 CDL，并且与时间上较远的 H1N1 株相比，比传统的血凝抑制和中和 MAb 具有更高的交叉反应性。一种茎特异性 MAb 对 H1 和 H2 血凝素具有亚型交叉反应性，表明茎特异性抗体在预防流感疾病方面具有作用，尤其是针对可能引起大流行的新型病毒亚型。
相似文献
1
Complement-dependent lysis of influenza a virus-infected cells by broadly cross-reactive human monoclonal antibodies.
J Virol. 2011 Dec;85(24):13463-7. doi: 10.1128/JVI.05193-11. Epub 2011 Oct 12.
2
A cross-reactive neutralizing monoclonal antibody protects mice from H5N1 and pandemic (H1N1) 2009 virus infection.
Antiviral Res. 2010 Dec;88(3):249-55. doi: 10.1016/j.antiviral.2010.09.007. Epub 2010 Sep 16.
3
[Monoclonal antibodies with high virus-neutralizing activity against pandemic influenza virus A/llV-Moscow/01/2009 (H1N1)swl].
Vopr Virusol. 2011 May-Jun;56(3):15-20.
4
Development and characterization of neutralizing monoclonal antibodies against the pandemic H1N1 virus (2009).
J Virol Methods. 2012 Jul;183(1):25-33. doi: 10.1016/j.jviromet.2012.03.016. Epub 2012 Apr 4.
5
Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for Protection in a Serum Transfer Mouse Challenge Model.
mBio. 2017 Sep 19;8(5):e01463-17. doi: 10.1128/mBio.01463-17.
6
Development of neutralizing monoclonal antibodies against the pandemic H1N1 virus (2009) using plasmid DNA immunogen.
J Virol Methods. 2014 Jan;195:54-62. doi: 10.1016/j.jviromet.2013.08.038. Epub 2013 Sep 20.
7
Potential Role of Nonneutralizing IgA Antibodies in Cross-Protective Immunity against Influenza A Viruses of Multiple Hemagglutinin Subtypes.
J Virol. 2020 Jun 1;94(12). doi: 10.1128/JVI.00408-20.
8
Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells.
PLoS One. 2008;3(12):e3942. doi: 10.1371/journal.pone.0003942. Epub 2008 Dec 16.
9
Development and characterization of a panel of cross-reactive monoclonal antibodies generated using H1N1 influenza virus.
Immunobiology. 2015 Aug;220(8):941-6. doi: 10.1016/j.imbio.2015.02.002. Epub 2015 Feb 14.
10
Development of a safe and convenient neutralization assay for rapid screening of influenza HA-specific neutralizing monoclonal antibodies.
Biochem Biophys Res Commun. 2010 Jul 2;397(3):580-5. doi: 10.1016/j.bbrc.2010.05.161.
引用本文的文献
1
Influenza-specific antibody-mediated and complement-dependent cellular cytotoxicity-inducing antibodies in vaccinated and infected pigs.
Front Immunol. 2025 Jun 30;16:1600761. doi: 10.3389/fimmu.2025.1600761. eCollection 2025.
2
Complement-mediated enhancement of SARS-CoV-2 antibody neutralisation potency in vaccinated individuals.
Nat Commun. 2025 Mar 18;16(1):2666. doi: 10.1038/s41467-025-57947-8.
3
Antibodies targeting the glycan cap of Ebola virus glycoprotein are potent inducers of the complement system.
Commun Biol. 2024 Jul 17;7(1):871. doi: 10.1038/s42003-024-06556-0.
4
Direct enhancement of viral neutralising antibody potency by the complement system: a largely forgotten phenomenon.
Cell Mol Life Sci. 2024 Jan 11;81(1):22. doi: 10.1007/s00018-023-05074-2.
5
Characterization of non-neutralizing human monoclonal antibodies that target the M1 and NP of influenza A viruses.
J Virol. 2023 Nov 30;97(11):e0164622. doi: 10.1128/jvi.01646-22. Epub 2023 Nov 2.
6
Use of Biolayer Interferometry to Identify Dominant Binding Epitopes of Influenza Hemagglutinin Protein of A(H1N1)pdm09 in the Antibody Response to 2010-2011 Influenza Seasonal Vaccine.
Vaccines (Basel). 2023 Jul 31;11(8):1307. doi: 10.3390/vaccines11081307.
7
Inducing broad-based immunity against viruses with pandemic potential.
Immunity. 2022 May 10;55(5):738-748. doi: 10.1016/j.immuni.2022.04.010.
8
Influenza Vaccination Results in Differential Hemagglutinin Stalk-Specific Fc-Mediated Functions in Individuals Living With or Without HIV.
Front Immunol. 2022 Apr 19;13:873191. doi: 10.3389/fimmu.2022.873191. eCollection 2022.
9
Complement-Mediated Neutralisation Identified in Ebola Virus Disease Survivor Plasma: Implications for Protection and Pathogenesis.
Front Immunol. 2022 Apr 12;13:857481. doi: 10.3389/fimmu.2022.857481. eCollection 2022.
10
Generation of a Universal Human Complement Source by Large-Scale Depletion of IgG and IgM from Pooled Human Plasma.
Methods Mol Biol. 2022;2414:341-362. doi: 10.1007/978-1-0716-1900-1_18.
本文引用的文献
1
Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection.
J Exp Med. 2011 Jan 17;208(1):181-93. doi: 10.1084/jem.20101352. Epub 2011 Jan 10.
2
Influenza virus vaccine based on the conserved hemagglutinin stalk domain.
mBio. 2010 May 18;1(1):e00018-10. doi: 10.1128/mBio.00018-10.
3
Induction of broadly neutralizing H1N1 influenza antibodies by vaccination.
Science. 2010 Aug 27;329(5995):1060-4. doi: 10.1126/science.1192517. Epub 2010 Jul 15.
4
Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses.
Proc Natl Acad Sci U S A. 2010 Jul 13;107(28):12658-63. doi: 10.1073/pnas.0911806107. Epub 2010 Jul 1.
5
Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine.
J Clin Invest. 2010 May;120(5):1663-73. doi: 10.1172/JCI41902. Epub 2010 Apr 12.
6
Complement and natural antibody are required in the long-term memory response to influenza virus.
Vaccine. 2008 Dec 30;26 Suppl 8:I86-93. doi: 10.1016/j.vaccine.2008.11.057.
7
Rediscovering complement, the first barrier of innate immunity.
Vaccine. 2008 Dec 30;26 Suppl 8:I1-2. doi: 10.1016/j.vaccine.2008.11.048.
8
Antibody recognition of a highly conserved influenza virus epitope.
Science. 2009 Apr 10;324(5924):246-51. doi: 10.1126/science.1171491. Epub 2009 Feb 26.
9
Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses.
Nat Struct Mol Biol. 2009 Mar;16(3):265-73. doi: 10.1038/nsmb.1566. Epub 2009 Feb 22.
10
Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion.
Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17736-41. doi: 10.1073/pnas.0807142105. Epub 2008 Nov 12.
Zotero 插件